[1]郝昱芳,安巧和△.乌司他丁联合谷氨酰胺治疗急性重症胰腺炎对患者血清淀粉酶、前白蛋白和白蛋白的影响*[J].陕西医学杂志,2020,49(10):1325-1328.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.033]
　HAO Yufang,AN Qiaohe..Effect of ulinastatin combined with glutamine on serum amylase,prealbumin and albumin in patients with severe acute pancreatitis[J].,2020,49(10):1325-1328.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.033]
点击复制

乌司他丁联合谷氨酰胺治疗急性重症胰腺炎对患者血清淀粉酶、前白蛋白和白蛋白的影响*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年10期
页码:
1325-1328
栏目:
药物与临床
出版日期:
2020-10-05

文章信息/Info

Title:
Effect of ulinastatin combined with glutamine on serum amylase,prealbumin and albumin in patients with severe acute pancreatitis
作者:
郝昱芳; 安巧和△
陕西省榆林市第二医院重症医学科(榆林 719000)
Author(s):
HAO Yufang; AN Qiaohe.
Department of Critical Medicine,Yulin No.2 Hospital,Shaanxi Province(Yulin 719000)
关键词:
乌司他丁;  谷氨酰胺;  急性重症胰腺炎;  淀粉酶;  前白蛋白;  白蛋白
Keywords:
Ulinastatin;  Glutamine;  Severe acute pancreatitis;  Amylase;  Prealbumin;  Albumin
分类号:
R657.5
DOI:
DOI:10.3969/j.issn.1000-7377.2020.10.033
文献标志码:
A
摘要:
目的:探讨乌司他丁联合谷氨酰胺治疗对急性重症胰腺炎患者血清淀粉酶、前白蛋白和白蛋白的影响。方法:将30例急性重症胰腺炎患者随机等比例分为常规组(n=15)与研究组(n=15),常规组予以乌司他丁治疗,研究组予以乌司他丁联合谷氨酰胺治疗,治疗14 d,比较两组临床症状改善时间(胃肠减压时间、腹痛缓解时间、首次自主排便时间、住院时间),血清相关指标(淀粉酶、前白蛋白、白蛋白)水平,炎症因子[肿瘤坏死因子-α(TNF-α)、白介素-10(IL-10)、干扰素-γ(INF-γ)]水平,免疫屏障功能[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)]以及预后[急性生理学与慢性健康状况评分量表(APACHE Ⅱ)评分]与不良反应发生的变化情况。结果:治疗14 d,研究组胃肠减压、腹痛缓解、首次自主排便以及住院时间显著短于常规组(P<0.05); 治疗14 d后,两组血清淀粉酶水平显著下调(P<0.05),前白蛋白、白蛋白水平显著上调(P<0.05),与常规组比较,研究组血清淀粉酶、前白蛋白、白蛋白水平更佳(P<0.05); 两组TNF-α、INF-γ显著下调(P<0.05),IL-10显著上调(P<0.05),与常规组进行比较,研究组TNF-α、INF-γ、IL-10水平更佳(P<0.05); 两组IgA、IgG、IgM显著上调(P<0.05),与常规组进行比较,研究组IgA、IgG、IgM水平更高(P<0.05); 两组APACHE Ⅱ评分显著降低(P<0.05),研究组下降幅度大于常规组(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:乌司他丁联合谷氨酰胺治疗急性重症胰腺炎患者可缩短临床症状改善时间,调节血清淀粉酶、前白蛋白以及白蛋白水平,抑制机体炎症反应,促进胃肠免疫功能,提高患者预后。
Abstract:
Objective:To explore the effect of ulinastatin combined with glutamine on serum amylase,prealbumin and albumin in patients with severe acute pancreatitis.Methods:30 patients with severe acute pancreatitis were randomly and evenly divided into conventional group(n=15)and study group(n=15).Conventional group was treated with ulinastatin,and study group was given ulinastatin combined with glutamine,and all patients were treated for 14 days.The improvement time of clinical symptoms(gastrointestinal decompression time,abdominal pain relief time,first spontaneous defecation time,hospital stay),serum related indicators(amylase,prealbumin,albumin),inflammatory factors(TNF-α,IL-10,INF-γ),immune barrier function(IgA,IgG,IgM),prognosis(APACHE Ⅱ score)and occurrence of adverse reactions were compared between the two groups.Results:After 14 days of treatment,the gastrointestinal decompression time,abdominal pain relief time,first spontaneous defecation time and hospital stay in study group were significantly shorter than those in conventional group(P<0.05).After 14 days of treatment,the serum amylase level in the two groups was significantly decreased(P<0.05),while the levels of prealbumin and albumin were significantly increased(P<0.05),and the levels of amylase,prealbumin and albumin in study group were better than those in conventional group(P<0.05).The TNF-α and INF-γ in the two groups were significantly decreased(P<0.05),while the IL-10 was significantly increased(P<0.05),and the levels of TNF-α,IL-10 and INF-γ in study group were better than those in conventional group(P<0.05).The levels of IgA,IgG and IgM were significantly increased in the two groups(P<0.05),and those of study group were better than those of conventional group(P<0.05).The APACHE Ⅱ score of the two groups was significantly lower(P<0.05),and the decrease range of the study group was greater than that of the conventionalal group(P<0.05).There was no significant difference in incidence rate of adverse reactions between the two groups(P>0.05).Conclusion:In the treatment of patients with acute severe pancreatitis,ulinastatin combined with glutamine can shorten the improvement time of clinical symptoms,regulate levels of serum amylase,prealbumin and albumin,inhibit the body inflammatory response,promote gastrointestinal immune function,and improve the prognosis of patients.

参考文献/References:

[1] 程相超.重症急性胰腺炎应用凉膈散联合乳果糖治疗对患者炎症反应的影响[J].陕西中医,2019,40(7):879-881.
[2] 余丹青,鲁海燕,呼 帮,等.乌司他丁治疗重症急性胰腺炎的疗效及可能机制[J].中国临床药学杂志,2017,26(5):283-287.
[3] 杜 姗,卜 爱.肠内营养治疗在重症监护室重症急性胰腺炎治疗中的临床研究[J].陕西医学杂志,2019,48(7):913-915.
[4] 何 清,王立为.营养支持、生长抑素联合乌司他丁治疗重症急性胰腺炎疗效分析[J].临床军医杂志,2018,46(3):248-250.
[5] 中华医学会外科学分会胰腺外科学组.急性胰腺炎诊治指南(2014版)[J].中华消化外科杂志,2015,14(1):1-5.
[6] 同永刚,杜工亮.乌司他丁与奥曲肽在治疗急性重症胰腺炎中临床疗效比较[J].陕西医学杂志,2018,47(3):371-372,375.
[7] 姜 萌,赵 鹏.奥曲肽联合加贝酯治疗重症急性胰腺炎疗效及对患者血清细胞因子水平的影响[J].陕西医学杂志,2020,49(2):212-215.
[8] 夏文菁.血清C反应蛋白、降钙素原及乳酸在重症急性胰腺炎中的变化及临床意义[J].标记免疫分析与临床,2017,24(7):766-769.
[9] 吴 军,唐 宁,黄婷婷,等.乌司他丁辅助治疗急性重症胰腺炎的疗效及对occludin、CRPI、IL-6水平的影响[J].现代生物医学进展,2018,18(18):203-206.
[10] 刘海洋.谷氨酰胺治疗急性重症胰腺炎的疗效分析及对炎性细胞因子与肝功能的影响[J].中国医药指南,2018,16(30):74-75.
[11] 苏建波,崔安宁,陈卫芳,等.谷氨酰胺联合乌司他丁、亚胺培南治疗急性重症胰腺炎疗效观察[J].河北医药,2018,40(22):35-38.
[12] 杨 成,文 静,夏 敏,等.谷氨酰胺营养支持对急性重症胰腺炎患者肠黏膜屏障功能及炎症反应程度的影响[J].海南医学院学报,2017,23(14):1896-1899.
[13] 甄海洋,朱 宁.乌司他丁对急性胰腺炎患者疗效及炎性因子的影响观察[J].河北医药,2016,38(12):1768-1770.
[14] 刘 博,王玉梅,周少英.强化谷氨酰胺的肠内营养联合微生态制剂对重症急性胰腺炎患者临床预后的影响[J].现代中西医结合杂志,2017,26(17):1838-1840.
[15] 郭法阔,张林尹红.谷氨酰胺早期肠内营养与动脉灌注联合用于重症急性胰腺炎的价值[J].现代消化及介入诊疗,2019,24(8):923-926.

相似文献/References:

[1]姬改娜,王彩琳.乌司他丁通过AMPK/Nrf2通路对急性肺损伤新生大鼠肺组织保护作用的实验研究[J].陕西医学杂志,2022,51(11):1323.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.001]
　JI Gaina,WANG Cailin.Protective effect of ulinastatin on lung tissue of neonatal rats with acute lung injury via AMPK/Nrf2 pathway[J].,2022,51(10):1323.[doi:DOI:10.3969/j.issn.1000-7377.2022.11.001]
[2]张百平,孙树凯,于庆伟,等.谷氨酰胺对脑出血小鼠神经保护和抗炎作用实验研究[J].陕西医学杂志,2023,52(2):128.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.002]
　ZHANG Baiping,SUN Shukai,YU Qingwei,et al.Neuroprotective and anti-inflammatory effects of glutamine in mice with intracerebral hemorrhage[J].,2023,52(10):128.[doi:DOI:10.3969/j.issn.1000-7377.2023.02.002]
[3]刘广精,王光权,黎天皇.乌司他丁联合依诺肝素治疗脓毒症并发急性肺损伤临床疗效及安全性研究[J].陕西医学杂志,2023,52(8):1071.[doi:DOI:10.3969/j.issn.1000-7377.2023.08.030]
　LIU Guangjing,WANG Guangquan,LI Tianhuang.Clinical efficacy and safety of ulinastatin combined with enoxaparin in treatment of sepsis complicated with acute lung injury[J].,2023,52(10):1071.[doi:DOI:10.3969/j.issn.1000-7377.2023.08.030]

备注/Memo

备注/Memo:
*陕西省卫生和计划生育委员会科研项目(2015JM02034)
更新日期/Last Update: 2020-10-10